EPISODE · Nov 2, 2012 · 9 MIN
Beyond the Plasma Cell: Proteasome Inhibition in Acute Myelogenous Leukemia
from Journal of Clinical Oncology (JCO) Podcast
In this podcast, Attar and colleagues explore whether patients aged 60-75 who enter remission with bortezomib added to standard anthracycline plus cytarabine chemotherapy during induction can be safely treated with intermediate dose cytarabine along with dose escalating bortezomib during consolidation. This regimen was tolerated at the highest dose of bortezomib tested, 1.3 mg/m2, and further randomized studies of this regimen will be planned.
NOW PLAYING
Beyond the Plasma Cell: Proteasome Inhibition in Acute Myelogenous Leukemia
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m